US Foods

Valbiotis announces that it has received Food and Drug Administration (FDA) approval for New Dietary Ingredient (NDI) status

Retrieved on: 
Tuesday, December 12, 2023

La Rochelle, December 11, 2023 (08:00 p.m. CEST) – Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a commercially-oriented company specializing in dietary supplements, committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces that it has received approval from the Food and Drug Administration (FDA) for New Dietary Ingredient (NDI) status for a plant extract present in all its TOTUM products.

Key Points: 
  • La Rochelle, December 11, 2023 (08:00 p.m. CEST) – Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a commercially-oriented company specializing in dietary supplements, committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces that it has received approval from the Food and Drug Administration (FDA) for New Dietary Ingredient (NDI) status for a plant extract present in all its TOTUM products.
  • The US Food and Drug Administration (FDA) imposes specific requirements on manufacturers and distributors wishing to market dietary supplements containing "new dietary ingredients".
  • Sébastien PELTIER, CEO and co-founder, emphasizes: "Obtaining the New Dietary Ingredient (NDI) status for this plant extract is a gratifying milestone, albeit expected, marking the conclusion of a standard authorization process.
  • This comes at a time when the growing incidence of metabolic and cardiovascular diseases worldwide poses a public health challenge."

Schizoaffective Disorder Drug Pipeline Research Report 2023 Featuring Lyndra Therapeutics, Luye Pharma Group, BioXcel Therapeutics, & Reviva Pharma - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 9, 2023

The "Schizoaffective Disorder - Pipeline Insight, 2023" report offers comprehensive insights into the Schizoaffective disorder pipeline landscape, encompassing information on more than 4 companies and over 4 pipeline drugs.

Key Points: 
  • The "Schizoaffective Disorder - Pipeline Insight, 2023" report offers comprehensive insights into the Schizoaffective disorder pipeline landscape, encompassing information on more than 4 companies and over 4 pipeline drugs.
  • The report delivers a thorough understanding of the current scenario and growth prospects within the Schizoaffective disorder indication.
  • It furnishes an extensive overview of the Schizoaffective disorder pipeline landscape, including information on the disease itself and treatment guidelines.
  • The assessment section of the report includes a comprehensive commercial assessment of Schizoaffective disorder, as well as a clinical evaluation of the pipeline products currently in development.

US Foods Reports Third Quarter Fiscal Year 2023 Earnings

Retrieved on: 
Thursday, November 9, 2023

US Foods Holding Corp. (NYSE: USFD), one of the largest foodservice distributors in the United States, today announced results for the third quarter fiscal year 2023.

Key Points: 
  • US Foods Holding Corp. (NYSE: USFD), one of the largest foodservice distributors in the United States, today announced results for the third quarter fiscal year 2023.
  • The ratio of Net Debt to Adjusted EBITDA was 2.9x at the end of the third quarter of fiscal 2023, compared to 3.5x at the end of fiscal 2022 and 3.7x at the end of the third quarter of fiscal 2022.
  • During the third quarter of fiscal 2023, the Company repurchased 0.7 million shares of common stock at an aggregate purchase price of $29 million.
  • During the third quarter of fiscal 2023, the Company acquired Renzi Foodservice, a broadline distributor in New York for a purchase price of $142 million.

Can HIV be cured using gene editing? We will soon find out

Retrieved on: 
Wednesday, November 8, 2023

To catch this virus was initially a death sentence, but today, thanks to antiretroviral drugs, it can be kept in check.

Key Points: 
  • To catch this virus was initially a death sentence, but today, thanks to antiretroviral drugs, it can be kept in check.
  • A small biotech company in San Francisco called Excision BioTherapeutics is trying to change that with its infusion, called EBT-101.
  • Despite the availability of antiretroviral drugs, hundreds of thousands of people still die from Aids each year.
  • Testing on larger groups of people and making the therapy affordable for everyone with HIV are crucial because the disease is more prevalent in poorer countries.

Propanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor Cells

Retrieved on: 
Tuesday, November 7, 2023

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that PRP enhances the sensitivity of resistant pancreatic tumor cells to standard chemotherapy treatment and alters the tumor microenvironment by decreasing the fibrotic tissue and its malignancy (ability to spread into surrounding tissues).

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that PRP enhances the sensitivity of resistant pancreatic tumor cells to standard chemotherapy treatment and alters the tumor microenvironment by decreasing the fibrotic tissue and its malignancy (ability to spread into surrounding tissues).
  • Various methods, including apoptosis (programmed cell death) and viability analysis, live/dead assays, and RT-qPCR (real time quantification of gene expression) analyses confirmed PRP enhances the sensitivity of pancreatic tumor cells to standard chemotherapy treatment and decreases expression of genes related to chemoresistance.
  • A synergistic ratio of 1:6 inhibits growth of most tumor cells.
  • Orphan Drug Designation status of PRP has been granted from the US Food and Drug Administration (FDA) for treatment of pancreatic cancer.

EQS-News: Biotest increases EBIT to Euro 125.4 million in the first nine months of 2023

Retrieved on: 
Tuesday, November 7, 2023

This development is due to the higher income taxes in connection with the earnings effect from technology disclosure and development services.

Key Points: 
  • This development is due to the higher income taxes in connection with the earnings effect from technology disclosure and development services.
  • This is equivalent to earnings per ordinary share of € 2.22 compared with € - 0.87 in the same period of the previous year.
  • In September 2023, Biotest also reached an important milestone in the marketing authorisation process for Yimmugo in the USA.
  • This revenue growth is enabled by the commissioning of the Yimmugo® production facility within Biotest Next Level.

Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 2, 2023

LONDON and RALEIGH, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the third quarter ended September 30, 2023, and provides a corporate update.

Key Points: 
  • PDUFA Target Action Date of June 26, 2024
    Conference call today at 9:00 a.m. EDT / 1:00 p.m. GMT
    LONDON and RALEIGH, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the third quarter ended September 30, 2023, and provides a corporate update.
  • Net loss: Net loss was $14.7 million for the third quarter ended September 30, 2023 (Q3 2022: $15.6 million).
  • Verona Pharma will host an investment community webcast and conference call at 9:00 a.m. EDT / 1:00 p.m. GMT on Thursday, November 2, 2023, to discuss the third quarter 2023 financial results and the corporate update.
  • An electronic copy of the third quarter 2023 results press release will also be made available today on the Company’s website.

Eargo Celebrates 1-Year Anniversary of FDA's Over-the-Counter (OTC) Hearing Aid Regulations, Driving a New Era of Accessibility and Innovation

Retrieved on: 
Wednesday, November 1, 2023

SAN JOSE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR) (“Eargo”) celebrates the one-year anniversary of the creation of an over-the-counter (OTC) hearing aid category in the US.

Key Points: 
  • SAN JOSE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR) (“Eargo”) celebrates the one-year anniversary of the creation of an over-the-counter (OTC) hearing aid category in the US.
  • Approximately 75% of Eargo survey respondents who had previously worn a traditional hearing aid indicated that Eargo’s performance was equal to or better than their traditional hearing aid.
  • To date, most plans have made no changes to the hearing aid benefits offered, and a handful of plans exclude coverage of OTC hearing aids.
  • Eargo’s commitment to accessibility and innovation envisions a future where hearing care is transformative and accessible to all Americans who need it.

Sysco Reports First Quarter Sales and Operating Income Growth; Reiterates Fiscal Year 2024 Guidance

Retrieved on: 
Tuesday, October 31, 2023

“Sysco delivered another quarter of compelling earnings results, growing operating income by 9.1% and adjusted operating income by 10.6%.

Key Points: 
  • “Sysco delivered another quarter of compelling earnings results, growing operating income by 9.1% and adjusted operating income by 10.6%.
  • “Our record first quarter operating profit, of $803.6 million, included meaningful gross margin expansion and positive operating leverage.
  • Foreign exchange rates increased both International Foodservice Operations sales by 3.2% and total Sysco sales by 0.6% during the quarter.
  • Foreign exchange rates increased both International Foodservice Operations operating income by 1.2% and total Sysco operating income by 0.1% during the quarter.

ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2023.

Key Points: 
  • ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2023.
  • We also continued to monitor the NSCLC cohort with IMGC936 and advanced dose escalation with IMGN151, our second-generation ADC targeting FRα.
  • Selling, general and administrative expenses were $37.7 million for the quarter ended September 30, 2023 compared to $33.6 million for the quarter ended September 30, 2022.
  • Capital expenditures were $1.6 million and $1.1 million for the first nine months of 2023 and 2022, respectively.